NCT04736355

DAOIB for the Treatment of Mild Cognitive Impairment

Completed Phase 2 Last updated 21 August 2024

What this trial tests

Phase 2 trial testing DAOIB in Mild Cognitive Impairment in 88 participants. Completed in 30 June 2024.

Timeline

1 January 2020

Primary endpoint
30 June 2024

30 June 2024

Quick facts

Lead sponsor	Chang Gung Memorial Hospital
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	88
Start date	1 January 2020
Primary completion	30 June 2024
Estimated completion	30 June 2024
Sites	1 location across Taiwan

Drugs / interventions tested

• DAOIB — full drug profile →
• Placebo

Conditions studied

• Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →

Sponsor

Chang Gung Memorial Hospital

Who can join

Adults 50 to 90, any sex, with Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

NMDA neurotransmission plays an important role in learning and memory. NMDA receptor-enhancing agent improved the cognitive function of patients with early-phase Alzheimer's disease. This study is a randomized, double-blind, placebo-controlled drug trial. All subjects will be allocated randomly to 2 groups: (1) DAOIB group; (2) placebo group. The study period is 24 weeks. The investigators hypothesize that DAOIB may yield better efficacy than placebo for cognitive function in patients with mild cognitive impairment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Sodium benzoate, a D-amino acid oxidase inhibitor, improved short-term memory in patients with mild cognitive impairment in a randomized, double-blind, placebo-controlled clinical trial.
   Lin CH, Wang SH, Lane HY. · · 2025 · cited 1× · PMID 40405827 · DOI 10.1111/pcn.13841